EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Advances in immunotherapies in ovarian cancer

Ruveyda Ayasun, Dmitriy Zamarin

Journal for ImmunoTherapy of Cancer · 2026-06 · 14 (6) · e014656

DOI: 10.1136/jitc-2025-014656 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 19.06.2026. Verfasst von Ruveyda Ayasun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Icahn School of Medicine at Mount Sinai, New York City, New York, USA. Hauptthemen laut MEDLINE: Immunotherapy, Ovarian Neoplasms. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pershing Square Foundation, Foundation for the National Institutes of Health, Ovarian Cancer Research Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer (OC) remains one of the deadliest gynecologic malignancies, and, despite the presence of tumor-infiltrating lymphocytes (TILs) in nearly half of cases, immune checkpoint inhibitors have shown only modest clinical benefit. These observations have stimulated interest in antigen-directed immunotherapies, including adoptive cell therapies (chimeric antigen receptor T cell, TIL therapy), bispecific antibodies, cancer vaccines, cytokine-based agents, and antibody–drug conjugates. Multiple targets, such as mesothelin, folate receptor-α, HER2, MUC16, EpCAM, and claudin-6, are currently under clinical investigation. In this review, we summarize the current landscape of immunotherapy in OC and examine the biological and clinical factors that have limited therapeutic efficacy to date. We also discuss emerging strategies aimed at overcoming resistance, including rational combinations and biomarker-driven approaches. Finally, we highlight the critical role of integrated genomic and immune profiling to elucidate mechanisms of response and resistance and to guide the next generation of immunotherapeutic strategies for OC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyOvarian NeoplasmsHumansFemaleAnimals

Stichwörter der Autor:innen

ImmunotherapyOvarian CancerTumor microenvironment - TME

Autor:innen und Institutionen

  • Department of Medicine, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
  • Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, New York, USA dmitriy.zamarin@mssm.edu.
  • Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Förderung

  • Pershing Square Foundation
  • Foundation for the National Institutes of Health
  • Ovarian Cancer Research Alliance

Zitieren

APA

Ayasun, R., & Zamarin, D. (2026). Advances in immunotherapies in ovarian cancer. Journal for ImmunoTherapy of Cancer, 14(6), e014656. https://doi.org/10.1136/jitc-2025-014656

Vancouver

Ayasun R, Zamarin D. Advances in immunotherapies in ovarian cancer. Journal for ImmunoTherapy of Cancer. 2026;14(6):e014656. doi:10.1136/jitc-2025-014656

BibTeX
@article{Ayasun2026,
  author = {Ayasun, Ruveyda and Zamarin, Dmitriy},
  title = {Advances in immunotherapies in ovarian cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {6},
  pages = {e014656},
  doi = {10.1136/jitc-2025-014656}
}
Kostenlos starten →